Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways

PPAR Research

Volumn , Issue , 2009, Pages

  Caron, Martine ^a,b,c   Vigouroux, Corinne ^a,b,c   Bastard, Jean Philippe ^a,b,c   Capeau, Jacqueline ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; IRBESARTAN; LAMIN A; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MESSENGER RNA; NELFINAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TELMISARTAN; TENOFOVIR; ZIDOVUDINE;

ADIPOCYTE; ADIPOSE TISSUE; CELL FUNCTION; CELLULAR DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 60049099162     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/507141     Document Type: Review

References (103)

1. Gougeon M.-L., Pénicaud L., Fromenty B., Leclercq P., Viard J.-P., Capeau J., Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations Antiviral Therapy 2004 9 2 161 177
2. Villarroya F., Domingo P., Giralt M., Lipodystrophy in HIV 1-infected patients: lessons for obesity research International Journal of Obesity 2007 31 12 1763 1776
3. Grinspoon S., Carr A., Cardiovascular risk and body-fat abnormalities in HIV-infected adults The New England Journal of Medicine 2005 352 1 48 62
4. Nolan D., Mallal S., Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms Antiviral Therapy 2004 9 6 849 863
5. Giralt M., Domingo P., Guallar J. P., HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy Antiviral Therapy 2006 11 6 729 740
6. Shibuyama S., Gevorkyan A., Yoo U., Tim S., Dzhangiryan K., Scott J. D., Understanding and avoiding antiretroviral adverse events Current Pharmaceutical Design 2006 12 9 1075 1090
7. Boyd M., Reiss P., The long-term consequences of antiretroviral therapy: a review Journal of HIV Therapy 2006 11 2 26 35
8. Haugaard S. B., Toxic metabolic syndrome associated with HAART Expert Opinion on Drug Metabolism and Toxicology 2006 2 3 429 445
9. Dubé M. P., Parker R. A., Tebas P., Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides AIDS 2005 19 16 1807 1818
10. Podzamczer D., Ferrer E., Sanchez P., Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study Journal of Acquired Immune Deficiency Syndromes 2007 44 2 139 147
11. Hansen A.-B. E., Lindegaard B., Obel N., Andersen O., Nielsen H., Gerstoft J., Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population HIV Medicine 2006 7 1 38 45
12. Mulligan K., Parker R. A., Komarow L., Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial Journal of Acquired Immune Deficiency Syndromes 2006 41 5 590 597
13. Podzamczer D., King M. S., Klein C. E., High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response HIV Clinical Trials 2007 8 4 193 204
14. Haubrich R. H., Riddler S., DiRenzo G., Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections (CROI '07) February 2007 Los Angeles, Calif, USA
15. Brinkman K., Smeitink J. A., Romijn J. A., Reiss P., Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy The Lancet 1999 354 9184 1112 1115
16. Lewis W., Day B. J., Copeland W. C., Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective Nature Reviews Drug Discovery 2003 2 10 812 822
17. Caron M., Auclair M., Lagathu C., The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro AIDS 2004 18 16 2127 2136
18. Walker U. A., Auclair M., Lebrecht D., Kornprobst M., Capeau J., Caron M., Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions Antiviral Therapy 2006 11 1 25 34
19. Caron M., Auclair M., Vissian A., Vigouroux C., Capeau J., Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues Antiviral Therapy 2008 13 1 27 38
20. Dowell P., Flexner C., Kwiterovich P. O., Lane M. D., Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors The Journal of Biological Chemistry 2000 275 52 41325 41332
21. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J., The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance Diabetes 2001 50 6 1378 1388
22. Caron M., Auclair M., Sterlingot H., Kornprobst M., Capeau J., Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation AIDS 2003 17 17 2437 2444
23. Lagathu C., Bastard J.-P., Auclair M., Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro Antiviral Therapy 2004 9 6 911 920
24. Vernochet C., Azoulay S., Duval D., Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines The Journal of Biological Chemistry 2005 280 3 2238 2243
25. Pacenti M., Barzon L., Favaretto F., Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs AIDS 2006 20 13 1691 1705
26. Viengchareun S., Caron M., Auclair M., Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes Antiviral Therapy 2007 12 6 919 929
27. Ben-Romano R., Rudich A., Török D., Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors AIDS 2003 17 1 23 32
28. Rudich A., Ben-Romano R., Etzion S., Bashan N., Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors Acta Physiologica Scandinavica 2005 183 1 75 88
29. Domingo P., Matias-Guiu X., Pujol R. M., Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy AIDS 1999 13 16 2261 2267
30. Bastard J. P., Lagathu C., Maachi M., Adipose tissue cytokines and insulin resistance Journées Annuelles de Diabétologie de l'Hôtel-Dieu 2004 29 37
31. Lagathu C., Kim M., Maachi M., HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo Biochimie 2005 87 1 65 71
32. Jones S. P., Janneh O., Back D. J., Pirmohamed M., Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors Antiviral Therapy 2005 10 2 207 213
33. Lagathu C., Eustace B., Prot M., Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages Antiviral Therapy 2007 12 4 489 500
34. Caron M., Auclair M., Donadille B., Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence Cell Death and Differentiation 2007 14 10 1759 1767
35. Ben-Romano R., Rudich A., Etzion S., Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents Antiviral Therapy 2006 11 8 1051 1060
36. Bastard J.-P., Caron M., Vidal H., Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance The Lancet 2002 359 9311 1026 1031
37. Jan V., Cervera P., Maachi M., Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients Antiviral Therapy 2004 9 4 555 564
38. Nolan D., Hammond E., Martin A., Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy AIDS 2003 17 9 1329 1338
39. Cherry C. L., Lal L., Thompson K. A., Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine Journal of Acquired Immune Deficiency Syndromes 2005 38 3 263 267
40. Domingo P., Vidal F., Domingo J. C., Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis European Journal of Clinical Investigation 2005 35 12 771 780
41. Farmer S. R., Regulation of PPAR γ activity during adipogenesis International Journal of Obesity 2005 29 supplement 1 S13 S16
42. Kintscher U., Law R. E., PPAR γ -mediated insulin sensitization: the importance of fat versus muscle American Journal of Physiology 2005 288 2 E287 E291
43. Medina-Gomez G., Gray S. L., Yetukuri L., PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism PLoS Genetics 2007 3 4 e64
44. Savage D. B., PPAR γ as a metabolic regulator: insights from genomics and pharmacology Expert Reviews in Molecular Medicine 2005 7 1 1 16
45. Semple R. K., Chatterjee V. K. K., O'Rahilly S., PPAR γ and human metabolic disease The Journal of Clinical Investigation 2006 116 3 581 589
46. Touyz R. M., Schiffrin E. L., Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications Vascular Pharmacology 2006 45 1 19 28
47. Heikkinen S., Auwerx J., Argmann C. A., PPAR γ in human and mouse physiology Biochimica et Biophysica Acta 2007 1771 8 999 1013
48. Casteilla L., Cousin B., Carmona M., PPARs and adipose cell plasticity PPAR Research 2007 2007 7
49. Farmer S. R., Molecular determinants of brown adipocyte formation and function Genes & Development 2008 22 10 1269 1275
50. Odegaard J. I., Ricardo-Gonzalez R. R., Goforth M. H., Macrophage-specific PPAR γ controls alternative activation and improves insulin resistance Nature 2007 447 7148 1116 1120
51. Rigamonti E., Chinetti-Gbaguidi G., Staels B., Regulation of macrophage functions by PPAR- α, PPAR- γ, and LXRs in mice and men Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 6 1050 1059
52. Planat-Benard V., Silvestre J.-S., Cousin B., Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives Circulation 2004 109 5 656 663
53. Al-Shali K. Z., House A. A., Hanley A. J. G., Khan H. M. R., Harris S. B., Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis Stroke 2004 35 9 2036 2040
54. Li A. C., Palinski W., Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis Annual Review of Pharmacology and Toxicology 2006 46 1 39
55. Duan S. Z., Ivashchenko C. Y., Whitesall S. E., Hypotension, lipodystrophy, and insulin resistance in generalized PPAR γ -deficient mice rescued from embryonic lethality The Journal of Clinical Investigation 2007 117 3 812 822
56. Kim S., Huang L.-W., Snow K. J., A mouse model of conditional lipodystrophy Proceedings of the National Academy of Sciences of the United States of America 2007 104 42 16627 16632
57. Reue K., Phan J., Metabolic consequences of lipodystrophy in mouse models Current Opinion in Clinical Nutrition and Metabolic Care 2006 9 4 436 441
58. Boguslavsky R. L., Stewart C. L., Worman H. J., Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy Human Molecular Genetics 2006 15 4 653 663
59. Capanni C., Mattioli E., Columbaro M., Altered pre-lamin A processing is a common mechanism leading to lipodystrophy Human Molecular Genetics 2005 14 11 1489 1502
60. Payne V. A., Grimsey N., Tuthill A., The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation Diabetes 2008 57 8 2055 2060
61. Zhang B., MacNaul K., Szalkowski D., Li Z., Berger J., Moller D. E., Inhibition of adipocyte differentiation by HIV protease inhibitors The Journal of Clinical Endocrinology & Metabolism 1999 84 11 4274 4277
62. Mondal D., Larussa V. F., Agrawal K. C., Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor α: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases AIDS Research and Human Retroviruses 2001 17 17 1569 1584
63. Roche R., Poizot-Martin I., Yazidi C. M.-E., Effects of antiretroviral drug combinations on the differentiation of adipocytes AIDS 2002 16 1 13 20
64. Vernochet C., Azoulay S., Duval D., Guedj R., Ailhaud G., Dani C., Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation AIDS 2003 17 15 2177 2180
65. Dowell P., Lane M. D., C/EBP α reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir Biochemical and Biophysical Research Communications 2005 327 2 571 574
66. Kudlow B. A., Jameson S. A., Kennedy B. K., HIV protease inhibitors block adipocyte differentiation independently of lamin A/C AIDS 2005 19 15 1565 1573
67. Kim R. J., Wilson C. G., Wabitsch M., Lazar M. A., Steppan C. M., HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism Obesity 2006 14 6 994 1002
68. Grigem S., Fischer-Posovszky P., Debatin K. M., Loizon E., Vidal H., Wabitsch M., The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes Hormone and Metabolic Research 2005 37 10 602 609
69. Noor M. A., Flint O. P., Maa J.-F., Parker R. A., Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically AIDS 2006 20 14 1813 1821
70. Carper M. J., Cade W. T., Cam M., HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus American Journal of Physiology 2008 294 3 E558 E567
71. De Barros S., Zakaroff-Girard A., Lafontan M., Galitzky J., Bourlier V., Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9 Journal of Pharmacology and Experimental Therapeutics 2007 320 1 291 299
72. Saillan-Barreau C., Tabbakh O., Chavoin J.-P., Casteilla L., Pénicaud L., Drug-specific effect of nelfinavir and stavudine on primary culture of human preadipocytes Journal of Acquired Immune Deficiency Syndromes 2008 48 1 20 25
73. Murata H., Hruz P. W., Mueckler M., The mechanism of insulin resistance caused by HIV protease inhibitor therapy The Journal of Biological Chemistry 2000 275 27 20251 20254
74. Ben-Romano R., Rudich A., Tirosh A., Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC- ζ Diabetologia 2004 47 6 1107 1117
75. Erbe D. V., Gartrell K., Zhang Y.-L., Molecular activation of PPAR γ by angiotensin II type 1-receptor antagonists Vascular Pharmacology 2006 45 3 154 162
76. Noor M. A., Parker R. A., O'Mara E., The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults AIDS 2004 18 16 2137 2144
77. Umpleby A. M., Das S., Stolinski M., Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy Antiviral Therapy 2005 10 5 663 670
78. Coffinier C., Hudon S. E., Farber E. A., HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells Proceedings of the National Academy of Sciences of the United States of America 2007 104 33 13432 13437
79. Lloyd D. J., Trembath R. C., Shackleton S., A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies Human Molecular Genetics 2002 11 7 769 777
80. Behrens G. M. N., Lloyd D., Schmidt H. H.-J., Schmidt R. E., Trembath R. C., Lessons from lipodystrophy: LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy AIDS 2000 14 12 1854 1855
81. Kosmiski L. A., Miller H. L., Klemm D. J., In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival Antiviral Therapy 2006 11 2 187 195
82. Stankov M. V., Lücke T., Das A. M., Schmidt R. E., Behrens G. M. N., Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors Antiviral Therapy 2007 12 2 205 216
83. Puigserver P., Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1- α International Journal of Obesity 2005 29 supplement 1 5 9
84. Pagel-Langenickel I., Bao J., Joseph J. J., PGC-1 α integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle The Journal of Biological Chemistry 2008 283 33 22464 22472
85. El Hadri K., Glorian M., Monsempes C., In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes The Journal of Biological Chemistry 2004 279 15 15130 15141
86. Riddle T. M., Kuhel D. G., Woollett L. A., Fichtenbaum C. J., Hui D. Y., HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus The Journal of Biological Chemistry 2001 276 40 37514 37519
87. den Boer M. A. M., Berbée J. F. P., Reiss P., Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 1 124 129
88. Goetzman E. S., Tian L., Nagy T. R., HIV protease inhibitor ritonavir induces lipoatrophy in male mice AIDS Research and Human Retroviruses 2003 19 12 1141 1150
89. Prot M., Heripret L., Cardot-Leccia N., Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice Antimicrobial Agents and Chemotherapy 2006 50 12 3998 4004
90. Mallon P. W. G., Unemori P., Sedwell R., In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA Journal of Infectious Diseases 2005 191 10 1686 1696
91. Kannisto K., Sutinen J., Korsheninnikova E., Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy AIDS 2003 17 12 1753 1762
92. Jones S. P., Qazi N., Morelese J., Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine-and zidovudine-containing regimens Journal of Acquired Immune Deficiency Syndromes 2005 40 5 565 572
93. Pace C. S., Martin A. M., Hammond E. L., Mamotte C. D., Nolan D. A., Mallal S. A., Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients Antiviral Therapy 2003 8 4 323 331
94. Chaparro J., Reeds D. N., Wen W., Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy Metabolism 2005 54 5 561 567
95. Kim M. J., Leclercq P., Lanoy E., A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study Antiviral Therapy 2007 12 8 1273 1283
96. Vigouroux C., Maachi M., Nguyen T.-H., Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy AIDS 2003 17 10 1503 1511
97. Sutinen J., Kannisto K., Korsheninnikova E., Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy American Journal of Physiology 2004 286 6 E941 E949
98. Slama L., Lanoy E., Valantin M.-A., Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113) Antiviral Therapy 2008 13 1 67 76
99. Guallar J. P., Gallego-Escuredo J. M., Domingo J. C., Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy AIDS 2008 22 5 575 584
100. Rodríguez de la Concepción M. L., Yubero P., Domingo J. C., Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes Antiviral Therapy 2005 10 4 515 526
101. Nedergaard J., Bengtsson T., Cannon B., Unexpected evidence for active brown adipose tissue in adult humans American Journal of Physiology 2007 293 2 E444 E452
102. Heilbronn L. K., Campbell L. V., Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity Current Pharmaceutical Design 2008 14 12 1225 1230
103. Dressman J., Kincer J., Matveev S. V., HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages The Journal of Clinical Investigation 2003 111 3 389 397